Clinical trials: Treatment Resistant Major Depressive Disorder
Major Depression
Effects of ECT on Monoamine Oxidase A in Depression Investigated With PET
This study aims at evaluating the effect of electroconvulsive therapy in treatment-resistant depressed patients on the major serotonin degrading enzyme in the human brain using neuroimaging methods, the monoamine oxidase A.
- Trial name
- NCT02379767
- Testing
- Electroconvulsive therapy, Positron emission tomography of the brain using [11C]harmine, Structural magnetic resonance imaging
- Where
- Austria
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Depression, Depressive Disorder
Buprenorphine for Treatment Resistant Depression
The purpose of this study is to compare the safety and efficacy of buprenorphine with placebo for adults with treatment resistant depression (TRD).
- Conditions
- Depression, Depressive Disorder, Depressive Disorder, Major
- Trial name
- BUP-TRD (NCT01407575)
- Testing
- Buprenorphine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Pittsburgh
Treatment Resistant Depression
Pulsating ElectroMagnetive Treatment (PEMF) at Treatment Resistant Depression
In this study patients with treatment resistant depression, as defined by Harold Sackeim, is subjected to daily sessions, for eight weeks, with Pulsating ElectroMagnetive Treatment (PEMF).
- Trial name
- PEMFII (NCT01353092)
- Testing
- Re5 Pulsating ElectroMagnetic Fields, Re5 Pulsating ElectroMagnetic Fields (PEMF)
- Where
- Denmark
- Volunteers
- 65 people
- Sponsor
- Hillerod Hospital, Denmark
Major Depressive Disorder (MDD), Treatment Resistant Depression (TRD)
Optimization of IV Ketamine for Treatment Resistant Depression
Existing treatments for major depressive disorder (MDD) generally take weeks to months to exert their maximal benefit. There is an urgent need to develop rapid-acting treatments for MDD.
- Trial name
- NCT00768430
- Testing
- Ketamine, Midazolam
- Where
- 2 sites in United States
- Volunteers
- 73 people
- Sponsor
- Baylor College of Medicine
Major Depressive Disorder (MDD)
The Effect of Transcranial Magnetic Stimulation Treatment on Microvasculature Stracture of the Retina and the Choroid
Transcranial Magnetic Stimulation (TMS) therapy is an approved and effective treatment option in treatment-resistant depression.
- Trial name
- TMS_OCT-A (NCT06708013)
- Testing
- Transcranial Magnetic Stimulation
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Gulhane Training and Research Hospital
Major Depressive Disorder
Aripiprazole Augmentation of SSRI Therapy in Treatment Refractory Depression
Our target population will have been adequately treated with one of three selective serotonin reuptake inhibitors (SSRIs; escitalopram, citalopram, or sertraline) for at least 8-12 weeks and continue to experience symptoms of…
- Trial name
- NCT00608543
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Texas Southwestern Medical Center
Severe Permanent Uni or Bilateral Non-pulsatile Tinnitus, Without Associated Vestibular Pathology
Evaluation of Deep Brain Stimulation (DBS) of the Right Operculum 3 (OP3) in Permanent Non-pulsatile Disabling Tinnitus (TINNOP3-DBS)
This pilot study aims at evaluating the effectiveness of the treatment of unilateral or bilateral, non-pulsatile, disabling, tinnitus, without vestibular dysfunction, using Deep Brain Stimulation (DBS) of the parieto-insular…
- Conditions
- Severe Permanent Uni or Bilateral Non-pulsatile Tinnitus, Without Associated Vestibular Pathology, Resistant to Therapeutic Failure, With or Without Hearing Loss
- Trial name
- TINNOP3-DBS (NCT04296097)
- Testing
- DBS
- Where
- France
- Volunteers
- 7 people
- Sponsor
- University Hospital, Grenoble
Major Depressive Disorder, Suicide
i-CBT and IV Ketamine for Suicidality in Treatment-Resistant Depression: A Randomized, Midazolam-Controlled Clinical Trial
Approximately four thousand Canadians die by suicide every year, and suicide is the second leading cause of death in youth and young adults (15-34 years).
- Conditions
- Major Depressive Disorder, Suicide, Treatment Resistant Depression
- Trial name
- Ket-CBT (NCT06480500)
- Testing
- Ketamine hydrochloride, i-CBT (Internet-based Cognitive Behavioural Therapy), Midazolam Hydrochloride
- Where
- Canada
- Volunteers
- 76 people
- Sponsor
- University Health Network, Toronto
Depression
Efficacy and Tolerability of Riluzole in Treatment Resistant Depression
This study aims to examine the antidepressant efficacy of riluzole, employing a randomized, double-blind, placebo-controlled, adjunctive trial in treatment-resistant major depressive disorder (TRD).
- Trial name
- NCT01204918
- Testing
- Riluzole
- Where
- 3 sites in United States
- Volunteers
- 104 people
- Sponsor
- Yale University
Major Depression
Antidepressant Effects of NR2B in Major Depression
Purpose : This study will determine whether MK-0657, a selective NR2B Antagonist, can quickly improve symptoms of depressed mood, psychomotor retardation, poor motivation and reduced enjoyment of things in patients with major…
- Trial name
- NCT00472576
- Testing
- MK-0657
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Institute of Mental Health (NIMH)
Major Depressive Disorder (MDD), Treatment Resistant Depression (TRD)
Electroconvulsive Therapy Augmented With Transcranial Magnetic Stimulation for Treatment Resistant Depression
The RTMSECT2 study was design to compare the application of electroconvulsive therapy augmented by transcranial magnetic stimulation.
- Trial name
- RMTSECT2 (NCT07324070)
- Testing
- Electroconvulsive therapy, Transcranial Magnetic Stimulation
- Where
- Czechia
- Volunteers
- 50 people
- Sponsor
- Charles University, Czech Republic
Major Depressive Disorder (MDD), Treatment-resistant Depression (TRD)
Comparison of Efficacy of Minocyclin and Celecoxib as Adjunctive Treatment in Treatment Resistant Cases of Major Depressive Disorder
This randomized controlled study was conducted to compare the effectiveness of minocycline and celecoxib as add-on treatments in patients with treatment-resistant major depressive disorder.
- Trial name
- NCT07804979
- Testing
- Minocycline, Celecoxib
- Where
- Pakistan
- Volunteers
- 78 people
- Sponsor
- Lahore General Hospital
Major Depressive Disorder (MDD), Treatment Resistant Depression (TRD)
Accelerated iTBS for Major Depression
Major depressive disorder (MDD) is a common and disabling psychiatric condition, and many patients do not achieve adequate response to standard antidepressant treatments.
- Trial name
- AIM-D (NCT07603804)
- Testing
- Accelerated Intermittent Theta Burst Stimulation (iTBS)
- Where
- Turkey (Türkiye)
- Volunteers
- 35 people
- Sponsor
- Istanbul University - Cerrahpasa
Multiple Sclerosis, Major Depressive Disorder
Acceptability and Feasibility of Transcranial Magnetic Stimulation (TMS) for Depression in Multiple Sclerosis
The goal of this single-arm, observational pilot study is to learn about the safety, feasibility, preliminary efficacy of TMS for the treatment of depression in people with MS.
- Conditions
- Multiple Sclerosis, Major Depressive Disorder, Treatment Resistant Depression
- Trial name
- NCT06329414
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Utah
Treatment-Resistant Major Depressive Disorder
Understanding Music and Mindfulness Preferences in Psilocybin-Assisted Psychotherapy
The goal of this pilot clinical trial is to learn whether it is feasible to individually tailor psilocybin-assisted psychotherapy (PAP) for people with treatment-resistant depression (TRD) based on their personal preferences.
- Trial name
- PPP (NCT07373535)
- Testing
- Psilocybin 25mg, Music-centered psilocybin-assisted therapy, Mindfulness-centered psilocybin-assisted therapy
- Where
- 2 sites in Canada
- Volunteers
- 16 people
- Sponsor
- Kyle Greenway
Major Depression Disorder
Molecular Signatures of TMS Response in Treatment-Resistant Depression
Transcranial Magnetic Stimulation (TMS) therapy is an approved and effective treatment option for treatment-resistant depression (TRD).
- Trial name
- PROMET_TMS (NCT07039370)
- Testing
- TMS
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Gulhane Training and Research Hospital
Depression
Effectiveness of Pramipexole for Treatment-Resistant Depression
This study will evaluate the effectiveness of pramipexole (Mirapex) in managing treatment-resistant depression.
- Trial name
- NCT00231959
- Testing
- Pramipexole (Mirapex)
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Massachusetts General Hospital
Depression, Major Depressive Disorder
Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression
Background: Most drugs that treat mood disorders take a long time to work. Ketamine works within hours. A dose can last for a week or more. Certain receptors in the brain might help ketamine work.
- Conditions
- Depression, Major Depressive Disorder, Major Depression
- Trial name
- NCT03973268
- Testing
- Arm 1, 2, 3 device interventions, Arm 2 Interventions, Arm 1, 2, 3 drug Interventions
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Institute of Mental Health (NIMH)
Depressive Disorder, Treatment-Resistant
Adaptive tDCS for Treatment-Resistant MDD
This pilot study aims to investigate the potential role of transcranial direct current stimulation (tDCS) in the treatment of treatment-resistant major depressive disorder (MDD).
- Trial name
- NCT02942368
- Testing
- tDCS
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Washington University School of Medicine
Bipolar Disorder
The Treatment of Children and Adolescents With Treatment-Resistant Depression
This study seeks to learn about brain function in adolescents with depression and to determine whether adding lithium carbonate to antidepressant medication can reduce depression in children and adolescents.
- Trial name
- NCT00029640
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- National Institute of Mental Health (NIMH)